Free Trial
NASDAQ:THAR

Tharimmune Q1 2024 Earnings Report

Tharimmune logo
$1.58 +0.05 (+3.26%)
As of 12:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tharimmune EPS Results

Actual EPS
-$2.85
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Tharimmune Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tharimmune Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Tharimmune's Q1 2025 earnings is scheduled for Thursday, May 8, 2025

Earnings Documents

Tharimmune Earnings Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Tharimmune announces FDA feedback on NDA path for TH104
See More Tharimmune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tharimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tharimmune and other key companies, straight to your email.

About Tharimmune

Tharimmune (NASDAQ:THAR), a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

View Tharimmune Profile

More Earnings Resources from MarketBeat